Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies

FierceBiotechIcon ends internal accounting investigation, finds it overstated revenue in prior years

FierceBiotechFDA extends Beren’s rare disease review after info request, further stretching saga

Endpoints NewsICON audit finds overstated revenue; Secretome and Psilera raise cash

Endpoints News#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project

FierceBiotechHoth Therapeutics’ pivot to AI in space sees stock rocket after rebrand

CellFarnesylation-driven KRAS phase separation promotes colon tumor growth

CellStructural basis of Wnt signalosome extracellular complex assembly

Endpoints NewsNiowave’s $75M radioisotope facility; CordenPharma to buy AmbioPharm

Endpoints NewsCharles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy

FierceBiotechHuman Longevity launches newco, teams with Insilico for AI-powered longevity research

FierceBiotechNovartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals

Promega BlogScreening Disease-Relevant Biology: How the Endo-GeneScreen Platform Uses Endogenous Protein Detection to Drive Drug Discovery